Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Firas El Chaer; Uma Borate; Rémy Duléry; Shernan G. Holtan; Arjun Datt Law; Lori Muffly; Samah Nassereddine; Rory M. Shallis; Kate Stringaris; Justin Taylor; Steven M. Devine; Mohamad Mohty; Christopher S. Hourigan

doi:10.1182/bloodadvances.2020003839

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Firas El Chaer
, Uma Borate
, Rémy Duléry
, Shernan G. Holtan
, Arjun Datt Law
, Lori Muffly
, Samah Nassereddine
, Rory M. Shallis
, Kate Stringaris
, Justin Taylor
, Steven M. Devine
, Mohamad Mohty
, Christopher S. Hourigan

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1757-1759
Number of pages	3
Journal	Blood Advances
Volume	5
Issue number	6
DOIs	https://doi.org/10.1182/bloodadvances.2020003839
State	Published - Mar 23 2021

Access to Document

10.1182/bloodadvances.2020003839

Cite this

@article{05f39d3f57ed490990bebf568c79af26,

title = "Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML",

author = "Chaer, \{Firas El\} and Uma Borate and R{\'e}my Dul{\'e}ry and Holtan, \{Shernan G.\} and Law, \{Arjun Datt\} and Lori Muffly and Samah Nassereddine and Shallis, \{Rory M.\} and Kate Stringaris and Justin Taylor and Devine, \{Steven M.\} and Mohamad Mohty and Hourigan, \{Christopher S.\}",

note = "Funding Information: Conflict-of-interest disclosure: U.B. has served as a consultant for Genentech and Bristol Myers Squibb and has research funding from Astellas. S.G.H. has served as a consultant for Incyte, Bristol Myers Squibb, and Generon. L.M. has research funding from Jasper, Adaptive, Astellas, and Servier and has served as a consultant for Pfizer and Amgen. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments: This work was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health (grant 1ZIAHL006163).",

year = "2021",

month = mar,

day = "23",

doi = "10.1182/bloodadvances.2020003839",

language = "English",

volume = "5",

pages = "1757--1759",

journal = "Blood Advances",

issn = "2473-9529",

number = "6",

}

TY - JOUR

T1 - Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

AU - Chaer, Firas El

AU - Borate, Uma

AU - Duléry, Rémy

AU - Holtan, Shernan G.

AU - Law, Arjun Datt

AU - Muffly, Lori

AU - Nassereddine, Samah

AU - Shallis, Rory M.

AU - Stringaris, Kate

AU - Taylor, Justin

AU - Devine, Steven M.

AU - Mohty, Mohamad

AU - Hourigan, Christopher S.

N1 - Funding Information: Conflict-of-interest disclosure: U.B. has served as a consultant for Genentech and Bristol Myers Squibb and has research funding from Astellas. S.G.H. has served as a consultant for Incyte, Bristol Myers Squibb, and Generon. L.M. has research funding from Jasper, Adaptive, Astellas, and Servier and has served as a consultant for Pfizer and Amgen. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments: This work was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health (grant 1ZIAHL006163).

PY - 2021/3/23

Y1 - 2021/3/23

UR - https://www.scopus.com/pages/publications/85103305080

U2 - 10.1182/bloodadvances.2020003839

DO - 10.1182/bloodadvances.2020003839

M3 - Comment/debate

C2 - 33755090

AN - SCOPUS:85103305080

SN - 2473-9529

VL - 5

SP - 1757

EP - 1759

JO - Blood Advances

JF - Blood Advances

IS - 6

ER -

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Access to Document

Other files and links

Cite this